Sakura Bio is a start-up company dedicated to developing an off-the-shelf, allogeneic T-cell therapy specifically designed to combat cancer. Our flagship product, SAK-T (Super Activated Killer T-cell), comprises a unique T-cell population with exceptional anti-tumor cytotoxic activity and absolutely no toxicity to healthy tissue. Developed by Professor Amnon Peled and Dr.

Inbal Mishalian at Hadassah Medical Center, our technology utilizes a straightforward and cost-effective proprietary manufacturing process. Unlike other T-cell therapies like CAR-T, SAK-T cells possess a high safety profile, devoid of Graft-versus-host disease (GVHD), and can be readily developed as an off-the-shelf T-cell product. Extensive preclinical studies have substantiated SAK-T's superior killing properties over CIK and other T-cell-based therapies across various tumor models.

With its remarkable efficacy in eliminating leukemic cells, Sakura Bio has chosen Acute Myeloid Leukemia (AML) as the inaugural indication for SAK therapy. Explore our website for more information about our team, science, and how to contact us